Oxaliplatin in Treating Patients With Persistent or Recurrent Endometrial Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed endometrial carcinoma that is refractory to curative therapy or established treatment
• * Clinically and/or histologically confirmed persistent or recurrent disease
• Measurable disease by physical examination or medical imaging
• * Sonography allowed if lesions are clearly defined on initial examination and bidimensionally measurable
• * Ascites or pleural effusions not considered measurable
• Must have received 1 prior cytotoxic therapy regimen
• * May include high-dose therapy, consolidation, or extended therapy after surgical or nonsurgical assessment
• * 1 additional noncytotoxic regimen allowed
• * Biologic or cytostatic agents include, but are not limited to:
• * Monoclonal antibodies
• * Cytokines
• * Small-molecule inhibitors of signal transduction
• Ineligible for a higher priority GOG protocol
• No known brain metastases
• PATIENT CHARACTERISTICS:
• Age
• 18 and over
• Performance status
• GOG 0-2 if received 1 prior therapy regimen
• GOG 0-1 if received 2 prior therapy regimens
• Life expectancy
• Not specified
• Hematopoietic
• Absolute neutrophil count at least 1,500/mm\^3
• Platelet count at least 100,000/mm\^3
• Hepatic
• Bilirubin no greater than 1.5 times upper limit of normal (ULN)
• SGOT no greater than 2.5 times ULN
• Alkaline phosphatase no greater than 2.5 times ULN
• Renal
• Creatinine no greater than 1.5 times ULN
• Cardiovascular
• No symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia
• Neurologic
• No sensory or motor neuropathy greater than grade 1
• No residual neuropathy attributed to prior chemotherapy or other chronic conditions (e.g., diabetes, venous stasis, or carpal tunnel syndrome)
• Other
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No history of allergy to platinum compounds or antiemetics
• No active infection requiring antibiotics
• No other uncontrolled illness
• No other invasive malignancies within the past 5 years except nonmelanomatous skin cancer
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• See Disease Characteristics
• At least 14 days since prior pegfilgrastim
• At least 24 hours since other prior growth factors
• At least 3 weeks since prior biologic or immunologic therapy
• No concurrent growth factors during first course of study therapy
• Chemotherapy
• See Disease Characteristics
• At least 4 weeks since prior chemotherapy and recovered
• No more than 1 prior cytotoxic chemotherapy regimen, either single or combination cytotoxic drug therapy
• No prior oxaliplatin
• Endocrine therapy
• At least 1 week since prior hormonal therapy directed at tumor
• Concurrent hormone replacement therapy allowed
• Radiotherapy
• At least 4 weeks since prior radiotherapy and recovered
• Surgery
• Recovered from any recent surgery
• Other
• At least 3 weeks since prior therapy for endometrial cancer
• No other concurrent investigational agents
• No prior anticancer therapy that would preclude study participation